Glycyl-tRNA synthetase (GARS)-associated neuropathy caused by a mutation in GARS is a hereditary axonal neuropathy involving motor functional impairment. In this review, we describe a novel GARS-associated mouse neuropathy model produced using an adenovirus vector system containing a neuron-specific promoter. These adenovirus vector-mediated animal models are based on GARS mutations and have been generated by viral delivery of GARS proteins to the long peripheral axons of mice. Using the highly efficient adenoviral vector system, the overexpression of mutated GARS proteins in animals is sufficient to induce the same phenotypes seen in patients, such as neuropathic pain and motor function impairment. Adenoviral vector-mediated animal models have been used to demonstrate the cellular distribution patterns of GARS mutants and their induced molecular changes. In addition, the GARS-associated neuropathy model has demonstrated that neuroinflammation mediated by microglial activation is a disease phenotype-causing factor. Thus, these adenoviral vector-mediated animal models provide valuable insights into GARS-associated axonopathy and may contribute to the development of therapeutic approaches.
Introduction
Glycyl-tRNA synthetase (GARS), which is ubiquitously expressed in all cell types, is a member of the family of aminoacyl-tRNA synthetases. Previous studies have shown that abnormal GARS proteins are linked to the pathogenesis of several human diseases (Ge et al. 1994; Sivakumar et al. 2005) . Certain mutations in the GARS gene are implicated in Charcot-Marie-Tooth (CMT) type 2D (CMT2D), an axonal neuropathy characterized by impaired motor function and sensory loss in the extremities (Antonellis et al. 2003) . Mutations in other positions of the GARS gene were found in distal spinal muscular atrophy type V (dSMA-V). Some mutations of GARS gene were found in both of the disorders. dSMA-V, a neuromuscular disorder, is an axonal neuropathy characterized by impaired motor function and the absence of sensory loss in the extremities compared with CMT2D (Antonellis et al. 2003; Barisic et al. 2008) . Both CMT2D and dSMA-V manifest as severe phenotypes in the upper extremities (Christodoulou et al. 1995; Sambuughin et al. 1998) . Multiple GARS mutations have been identified in patients with these diseases: A57V, E71G, L129P, G240R, P244L, I280F, H418R, D500N, G526R, S581L and G598A (Christodoulou et al. 1995; Ionasescu et al. 1996; Sambuughin et al. 1998; Antonellis et al. 2003; Sivakumar et al. 2005; Del Bo et al. 2006; James et al. 2006; Rohkamm et al. 2007 ; Abe & Hayasaka 2009 ). L129P, H418R and G526R are involved only in dSMA-V and G240R, P244L and I280F are involved only in CMT2D, but E71G and D500N are involved in either CMT2D or dSMA-V (Christodoulou et al. 1995; Ionasescu et al. 1996; Sambuughin et al. 1998; Antonellis et al. 2003; Sivakumar et al. 2005; Del Bo et al. 2006; James et al. 2006; Rohkamm et al. 2007; Abe & Hayasaka 2009 ). Most of dSMA-V-or CMT2D-associated mutations have a range of effects on dimer interactions, whereas L129P and G240R GARS mutations have less capacity to form dimer (Nangle et al. 2007) .
Two previous in vitro studies evaluated the localization patterns of CMT-causing GARS mutants (Antonellis et al. 2006; Nangle et al. 2007 ). Antonellis et al. showed that the wild-type (WT) GARS protein exists in a granular form within the cell body and neurite projections, whereas the non-granular G240R and L129P mutants were distributed diffusely throughout the entire cell (Antonellis et al. 2006 ). In the study, G240R mutant was expressed and yielded a normal amount of the GARS protein. In functional analysis of GARS mutants, some mutants showed loss of function. Thus, the authors proposed that GARS-associated neuropathy is caused by loss-of-function of GARS mutations. In contrast, Nangle et al. found a diffuse expression pattern for WT GARS in neuroblastoma cells, whereas the G240R and L129P mutants were present at lower levels and within neurite projections (Nangle et al. 2007 ).
Here, we introduce studies that used adenoviral vectors to overexpress GARS axonopathy-causing mutants. The ability of adenoviral vectors to deliver GARS mutants specifically into peripheral nerve axons has allowed experimental analysis of the pathological processes involved in the abnormal localization of GARS mutants (Seo et al. 2014a (Seo et al. , 2014b . In addition, the use of adenoviral vectors has led to the generation of GARS axonopathy animal models of neuropathic pain and motor impairment, which are symptoms in human patients (Lee et al. 2014; Seo et al. 2014c ). Therefore, highly efficient adenoviral vectors for in vivo application in peripheral nerves offer an approach to overcome the limitations of using genetically modified transgenic mice, which lack specificity to long peripheral axons.
Adenoviral vector expression in vivo
A strategy to create neuron-specific animal models is to overexpress dominant GARS mutant genes. Animal models enable manifestation of morphological and functional phenotypes (Lee et al. 2014; Seo et al. 2014a Seo et al. , 2014b Seo et al. , 2014c . The promoter of the mouse choline acetyltransferase (ChAT) gene, which includes a neuron-restrictive silencer element and cholinergic-specific enhancer, key regulatory elements for neuron-specific expression, has been used in these models (Misawa et al. 1992; Lönner-berg et al. 1996) . Neuron-specific recombinant adenoviruses are injected into the sciatic nerve for anterograde and retrograde transduction (Lee et al. 2014; Seo et al. 2014a Seo et al. , 2014b Seo et al. , 2014c .
The adenoviral vector system expresses flag-tagged human GARS (hGARS) under the control of ChAT promoter ( Figure 1 ). Green fluorescent protein (GFP) expression from the adenoviral vector is under control of the Cytomegalovirus (CMV) promoter ( Figure 1 ). Because the expressed GFP is translated from a distinct transcript driven by a CMV promoter, Schwann cells and axons surrounding the long peripheral axon cell bodies infected by the virus vectors exhibit GFP-positive signals (Lee et al. 2014; Seo et al. 2014a Seo et al. , 2014b . However, specific expression of WT or mutant GARS in peripheral neurons can be identified though detection of the flag-tag linked to the GARS gene terminus (Lee et al. 2014; Seo et al. 2014a Seo et al. , 2014b . Thus, in vivo application of adenoviruses is highly efficient for the induction of neuron-specific expression of flag-tagged hGARS fusion proteins in long peripheral axons.
Defects in GARS mutant protein distribution in peripheral axons in vivo
Previously mentioned studies have shown considerably different results with respect to the cellular distribution of WT or L129P and G240R mutant hGARS proteins (Antonellis et al. 2006; Nangle et al. 2007 ). However, because the distribution patterns of these mutants have not been demonstrated in vivo using animal models or human samples, the discrepancies among studies require resolution using a suitable animal model to assess localization patterns of WT and mutant hGARS proteins.
The overexpression of GARS proteins enabled demonstration of defects in GARS mutant distribution in peripheral axons in vivo. GARS axonopathy animal models using adenoviruses expressing flag-tagged hGARS fusion proteins have enabled identification of WT or L129P and G240R mutant protein distributions in sciatic nerves, the dorsal root ganglion (DRG), spinal dorsal horn and spinal ventral horn (Seo et al. 2014a (Seo et al. , 2014b . In L129P and G240R mutant hGARS-expressing mouse models, these mutants were present at lower levels in sciatic nerve fibers and the Figure 1 . Schematic representation of the promoter and expression units in each adenovirus (GARS WT, L129P and G240R) (Seo et al. 2014a (Seo et al. , 2014b spinal dorsal horn (Seo et al. 2014a (Seo et al. , 2014b , compared with WT GARS. However, in motor neuronal cell bodies of the spinal ventral horn and sensory neuronal cell bodies of the DRG, L129P and G240R hGARS mutants were expressed in a pattern similar to that of WT GARS (Seo et al. 2014a (Seo et al. , 2014b . These results demonstrated that L129P and G240R GARS mutants have a significant distribution defect in the peripheral and central axons of DRG neurons and in the peripheral axons of motor neurons, consistent with a previous in vitro study (Antonellis et al. 2006 ). In addition, the distribution defect in long peripheral axons suggested the possible involvement of a pathogenic mechanism in axon length dependency (Seo et al. 2014b) .
Because GARS neuropathy is a type of axonopathy, myelin sheaths of both WT and mutant hGARS-expressing sciatic nerves should be conserved in animal models infected with adenoviral vectors. In previous studies, adenovirus-infected sciatic nerves showed only minimal differences in myelin sheath proteins (MBP and P0) compared with non-infected controls (Seo et al. 2014a (Seo et al. , 2014b . Thus, the adenovirus-based GARS-associated axonopathy mouse model may be a useful tool to examine human gene distributions in the peripheral nerve.
Adenoviral vector-mediated animal models of neuropathic pain
In CMT patients, neuropathic pain is often a symptom of CMT disease (Carter et al. 1998; Pazzaglia et al, 2010; Ribiere et al. 2012) . Because neuropathic pain is a common consequence of damage to the nervous system (Baron 2009 ), in CMT patients it is involved in peripheral nerve malfunction induced by CMT-associated mutated proteins. Many animal models of neuropathic pain have been developed and have shown that the activation of spinal microglia in the spinal dorsal horn influences the induction of neuropathic pain (Woolf & Salter 2000; Tsuda et al. 2003; Tsuda et al. 2005; Costigan et al. 2009) .
A GARS axonopathy mouse model for neuropathic pain has been constructed using WT or L129P and G240R mutant GARS-expressing adenoviral vectors (Lee et al. 2014) . By evaluating several markers for pain induction and nerve damage, including p-ERK, activating transcription factor 3 (ATF3) and Iba1 (Ma & Quirion 2002; Ivanavicius et al. 2007; Bráz & Basbaum 2010; Maeda et al. 2010) , this model was used to demonstrate the anatomical and functional phenotypes of neuropathic pain (Lee et al. 2014) .
The appearance of allodynia dramatically increased the number of microglia on the injured side of the spinal cord (Tsuda et al. 2003 (Tsuda et al. , 2005 Watkins & Maier 2003; Marchand et al. 2005; Maeda et al. 2010 ). The adenoviral vectormediated mouse model indicated that the expression of L129P and G240R GARS mutant proteins in the central axon terminals of the spinal cord increases the number of activated microglia (Lee et al. 2014 ). This was sufficient to induce neuropathic pain in a mutant GARS-induced neuropathy model. In addition, an adenoviral vector-mediated neuropathic animal model showed strong ATF3 expression in mutant GARS-expressing DRG neurons, whereas ATF expression was not detected in WT GARS-expressing DRG neurons (Lee et al. 2014) . Several studies have monitored the induction of ATF3 in the injured nerve and suggested that stimuli in the peripheral nerves induce the expression of ATF3 in DRG neurons in animal models of neuropathic pain (Tsujino et al. 2000; Ivanavicius et al. 2007; Bráz & Basbaum 2010) . Thus, it seems likely that the adenoviral vector-mediated expression of mutant GARS proteins in DRG sensory neurons induces ATF3 activation, which in turn affects the recruitment of microglia to the stimulated central axon terminals of DRG neurons. Consequentially, this microglial activation contributes to the initiation of neuropathic pain in adenoviral vector-mediated GARS-induced neuropathies. However, further evaluation is necessary to identify the relationship between the defects in mutant GARS distribution and CMT-associated neuropathic pain. Therefore, adenovirus-mediated animal models may represent a new approach to discovery of therapeutic targets for CMT-associated neuropathic pain.
Adenoviral vector-mediated animal models for motor impairment
GARS-associated axonopathy is a neurodegenerative axonal neuropathy characterized by impaired motor function (Antonellis et al. 2003) . Of the GARS-associated axonopathies, dSMA-V is a neuromuscular disorder characterized by the presence of impaired motor function and the absence of sensory loss (Barisic et al. 2008) . However, the underlying mechanisms of motor impairment in dSMA-V and other GARS-associated neuropathies are unclear. Thus, the construction of adenoviral vectormediated animal models can help to identify the mechanisms underlying motor impairment in these neuropathies.
Amyotrophic lateral sclerosis (ALS) is an inherited neurodegenerative disease characterized by the progressive loss of upper and lower motor neurons. Understanding the pathophysiology of ALS may help demonstrate the underlying mechanisms of motor impairment in GARS-associated neuropathies. Familial ALS is caused prominently by mutations in the ubiquitously expressed superoxide dismutase 1 (SOD1) (Rosen 1993) or C9ORF72 (Rohrer et al. 2015) . Hexanucleotide repeat expansions of C9ORF72 gene is a crucial point in neurodegenerative diseases including ALS, dementia and so forth (DeJesus-Hernandez et al, 2011; Renton et al, 2011) . However, the mechanism of neurodegeneration, except for clinical evidences, through C9ORF72 repeat expansions still remains to be elucidated. Two studies reported that microglia is associated with motor impairment in ALS (Boillée et al. 2006; Dibaj et al. 2012 ). Thus, these findings support the possibility that GARS mutation-induced neuroinflammation is a mechanism for GARS-associated neuropathies, similar to that of neuronal degeneration in ALS.
An animal model incorporating an adenoviral vector system demonstrated that neuroinflammation is a potential mechanism underlying dSMA-V phenotypes (Seo et al. 2014c) . In previous studies, ATF3 activation by injurious stimuli was associated with deterioration of motor neurons (Tsujino et al. 2000; Hai & Hartman 2001; Vlug et al. 2005; de Waard et al. 2010 ) and with cell death programs (Hai & Hartman 2001; Nakagomi et al. 2003; Raivich et al. 2004) . In this animal model, ATF3 expression was increased in L129P mutant hGARS-expressing motor neurons compared with WT hGARS-expressing neurons; in addition, the regions near motor neurons in the L129P-expressing ventral horn were surrounded by more Iba1-positive microglial cells compared with the WT-expressing ventral horn (Seo et al. 2014c ). These results indicate that in dSMA-V, the expression of L129P mutant hGARS induces ATF3 activation in ventral motor neurons, and ATF3 activation triggers motor cell death programs through neuroinflammation mediated by microglia, similarly to the effects on ATF3 and microglia in ALS (Vlug et al. 2005; Beers et al. 2006; Boillée et al. 2006; Yamanaka et al. 2008) .
dSMA-V, caused by a GARS mutation, is a peripheral neuropathy characterized by progressive weakness and atrophy. To identify motor dysfunction in a dSMA-V mouse model, the rotarod test was performed in the accelerating mode. Immediately after the sciatic nerves were infected with the adenovirus, both WT and L129P mutant hGARS-expressing mice showed severe motor impairment on the graph (Figure 2 ). Sham-operated mice were only sutured on the skin after an incision of the musculus gluteus superficialis without any viral infection. Thus, the severe performance decline seen in sham-operated, WTand L129P mutant-expressing mice may be due to posttraumatic behavior resulting from the surgical procedures rather than from motor impairment. Over time, however, the WT hGARS-expressing mice exhibited significantly improved performance on this test compared with the L129P mutant-expressing mice, and the motor impairment in the latter was unchanged for 7 days after adenoviral infection (Figure 2 ). In addition, the fixed bar and modified tail suspension tests indicated that L129P-expressing mice showed abnormal coordinated motor activity in the peripheral nerves (Seo et al. 2014c ). Thus, in this viral vectormediated animal model, behavioral measures of peripheral nerve dysfunction appeared useful for assessing motor function as well as understanding morphological phenotypes in dSMA-V.
Conclusions
The underlying mechanisms of CMT disease, a hereditary neurodegenerative axonal neuropathy, have been evaluated recently. In GARS axonopathy, especially, the current belief is that GARS protein mutations may induce enzyme malfunction, including loss of function, protein aggregation, mischarging, nucleolar dysfunction and abnormal dimerization. In addition, non-canonical functions, such as abnormal axonal transport seen in GARS mutants, may be one of the causes of GARS axonopathy.
Transgenic animal models represent a useful tool for identifying the exact functions of target molecules in in vivo systems. However, because genetically modified transgenic mouse models have several disadvantages, such as a long construction time, expense, and a low chance of success, further evaluation of target molecules is difficult. Thus, adenoviral vector in vivo approaches offer more feasible and rapid results than do transgenic mouse cell lines.
Here, we introduced recent reports that demonstrated the use of adenoviral vectors to construct neuroinflammatory GARS axonopathy animal models. These animal models have been sufficient to evaluate the morphological, molecular and functional phenotypes of GARS axonopathy and the underlying mechanisms. Thus, the construction of more efficient animal models using adenoviral vectors may provide useful drug-screening tools for tools for various types of neuropathies, as well as CMT disease or Guillain-Barré syndrome. Mice underwent three trials of a maximum 5 min per day with 45-60-min inter-trial intervals for 7 consecutive days (Con, n = 6; Sham, n = 4; WT, n = 6; L129P, n = 6). The rotarod accelerated from 0 to 40 rpm over a 120-s period, after which 40 rpm was maintained.
